Drug Trial Radar · NCT04767529
A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
Last checked: Nov 19, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
128
Actual
Start
Feb 16, 2021
Primary completion
May 2, 2024
Study completion May 2, 2024
Sponsor
- Lead sponsor
- Akero Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in non-cirrhotic subjects with biopsy-proven F2 - F3 NASH.
Conditions
- NASH - Nonalcoholic Steatohepatitis
Interventions
EfruxiferminDrug
subcutaneous injection
PlaceboDrug
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effect of Efruxifermin (EFX) vs Placebo on Fibrosis Regression in Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)-Associated Stage 2 or 3 Fibrosis (F2 or F3)Time frame: 24 Weeks
Locations
55 sites in 2 countries. Site status is shown where the registry gives one.
Akero Clinical Study Site
Chandler, Arizona
Akero Clinical Study Site
Glendale, Arizona
Akero Clinical Study Site
Tucson, Arizona
Akero Clinical Study Site
North Little Rock, Arkansas
Akero Clinical Study Site
Chula Vista, California
Akero Clinical Study Site
Fresno, California
Akero Clinical Study Site
La Jolla, California
Akero Clinical Study Site
Los Angeles, California
Akero Clinical Study Site
Los Angeles, California
Akero Clinical Study Site
Los Angeles, California
Akero Clinical Study Site
Orange, California
Akero Clinical Study Site
Panorama City, California
Akero Clinical Study Site
Rialto, California
Akero Clinical Study Site
Santa Ana, California
Akero Clinical Study Site
Fort Myers, Florida
Akero Clinical Study Site
Inverness, Florida
Akero Clinical Study Site
Lakewood Rch, Florida
Akero Clinical Study Site
Miami, Florida
Akero Clinical Study Site
Miami, Florida
Akero Clinical Study Site
Miami Lakes, Florida
Akero Clinical Study Site
Ocala, Florida
Akero Clinical Study Site
Sarasota, Florida
Akero Clinical Study Site
Marietta, Georgia
Akero Clinical Study Site
Topeka, Kansas
Akero Clinical Study Site
Baton Rouge, Louisiana
Akero Clinical Study Site
Marrero, Louisiana
Akero Clinical Study Site
Ypsilanti, Michigan
Akero Clinical Study Site
Flowood, Mississippi
Akero Clinical Study Site
Jackson, Mississippi
Akero Clinical Study Site
Las Vegas, Nevada
Akero Clinical Study Site
Charlotte, North Carolina
Akero Clinical Study Site
Durham, North Carolina
Akero Clinical Study Site
Morehead City, North Carolina
Akero Clinical Study Site
Cincinnati, Ohio
Akero Clinical Study Site
Greenville, South Carolina
Akero Clinical Study Site
Hermitage, Tennessee
Akero Clinical Study Site
Nashville, Tennessee
Akero Clinical Study Site
Arlington, Texas
Akero Clinical Study Site
Austin, Texas
Akero Clinical Study Site
Cedar Park, Texas
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.